Insmed (INSM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Apr, 2026Voting matters and shareholder proposals
Election of two Class II directors, Elizabeth McKee Anderson and Clarissa Desjardins, Ph.D., to serve until the 2029 Annual Meeting of Shareholders.
Advisory vote on the 2025 compensation of named executive officers.
Ratification of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026.
Other business may be considered as may properly come before the meeting or any adjournment or postponement.
Board of directors and corporate governance
Board recommends voting for all director nominees and all proposals presented.
Executive compensation and say-on-pay
Shareholders will cast an advisory vote on the 2025 compensation of named executive officers.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Insmed
- 44% growth and high patient retention drive confidence in $1B+ revenue and future expansion.INSM
RBC Capital Markets Global Healthcare Conference 202620 May 2026 - Strong Q1 2026 growth and clinical advances drive expansion in respiratory and rare disease markets.INSM
Investor presentation20 May 2026 - All agenda items passed, including director elections and auditor ratification, with no questions.INSM
AGM 202619 May 2026 - Strong launch momentum and pipeline advances set the stage for robust future growth.INSM
Bank of America Global Healthcare Conference 202612 May 2026 - Q1 2026 revenues soared 230% to $306M, driven by BRINSUPRI and ARIKAYCE growth.INSM
Q1 20267 May 2026 - Record 2025 revenues, major product approvals, and strong governance set the stage for continued growth.INSM
Proxy filing1 Apr 2026 - Late-stage pipeline and strong launches position for major growth and label expansions.INSM
Investor presentation25 Mar 2026 - ARIKAYCE improved symptoms and culture conversion, supporting label expansion in MAC lung disease.INSM
Study result23 Mar 2026 - Major clinical milestones and strong commercial execution drive growth across key therapeutic areas.INSM
Leerink Global Healthcare Conference 202610 Mar 2026